Android app Apple app link

Wells Fargo Raises Kyverna Therapeutics (KYTX) PT to $27 on Confidence in KYV-101 Stiff Person Syndrome Trial Readout

By Yahoo! Finance   |   1 month ago
Wells Fargo Raises Kyverna Therapeutics (KYTX) PT to $27 on Confidence in KYV-101 Stiff Person Syndrome Trial Readout

Kyverna Therapeutics Inc. (NASDAQ:KYTX) is a promising young stock with high potential, receiving positive analyst reviews. The company focuses on developing cell therapies for autoimmune diseases, with its lead candidate KYV-101 showing promising results.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.